Active, not recruitingPhase 1NCT04106219
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- LY3295668 Erbumine(drug)
- Enrollment
- 71 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2020 – 2026
Study locations (17)
- UCSF Medical Center at Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- University of Chicago - Comer Children's Hospital, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Childrens Hospital, Houston, Texas, United States
- Perth Children's Hospital, Perth, Western Australia, Australia
- UZ Gent, Ghent, Oost-Vlaanderen, Belgium
- Centre Leon Berard, Lyon, Auvergne-Rhône-Alpes, France
- Institut Curie, Paris, France
- Universitätsklinikum Köln, Cologne, Germany
- Istituto Nazionale dei Tumori, Milan, Lombardy, Italy
- National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain
- +2 more locations on ClinicalTrials.gov
Collaborators
New Approaches to Neuroblastoma Therapy Consortium (NANT) · Innovative Therapies for Children with Cancer in Europe (ITCC)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04106219 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University